Home Business Grants Notice of Intent to Publish a Funding Opportunity Announcement for Exploring the…
Notice of Intent to Publish a Funding Opportunity Announcement for Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes (R21, Clinical Trial Optional)
| Opportunity ID: | 310844 |
| Opportunity Number: | NOT-AT-19-009 |
| Opportunity Title: | Notice of Intent to Publish a Funding Opportunity Announcement for Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes (R21, Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | |
| CFDA Number(s): | 93.213 |
| Eligible Applicants: | State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | |
| Agency Code: | HHS-NIH11 |
| Agency Name: | Department of Health and Human Services National Institutes of Health |
| Posted Date: | Dec 04, 2018 |
| Last Updated Date: | Dec 04, 2018 |
| Estimated Synopsis Post Date: | Jan 08, 2019 |
| Fiscal Year: | 2019 |
| Award Ceiling: | $150,000 |
| Award Floor: | |
| Estimated Total Program Funding: | $1,500,000 |
| Expected Number of Awards: | 6 |
| Description: | The National Center for Complementary and Integrative Health (NCCIH) intends to publish a Funding Opportunity Announcement (FOA) to solicit applications for research on minor cannabinoids and terpenes in the cannabis plant as it relates to pain and nociception. Minor cannabinoids are defined as all and any cannabinoids from the cannabis herb other than Δ9-tetrahydrocannabinol (Δ9-THC). Cannabinoids and terpenes of particular interest include: Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), Myrcene, β-caryophyllene, Limonene, α-terpineol, Linalool, α-phellandrene, α-pinene, β-pinene, γ-terpinene, and α-humulene. This initiative intends to support highly innovative basic and/or mechanistic studies in appropriate model organisms and/or human subjects aiming to identify, describe and predict if minor cannabinoids and/or terpenes can help treat pain. The mechanisms and processes underlying potential contribution of minor cannabinoids and terpenes to pain relief and functional restoration in patients with different pain conditions may be very broad. This initiative encourages interdisciplinary collaborations by experts from multiple fields—pharmacologists, chemists, physicists, physiologists, neuroscientists, psychologists, endocrinologists, immunologists, geneticists, behavioral scientists, clinicians, and others in relevant fields of inquiry. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects, as well as to give potential applicants sufficient time to determine whether they need to obtain investigator registration and site licensure from the Drug Enforcement Agency (DEA) ,if appropriate. For applications that include human use of any of the compounds, this Notice provides time to determine whether an Investigational New Drug (IND) application is needed, or if the FDA will provide a written waiver indicating that an IND is not needed for the proposed research. No awards will be made to the investigators in the absence of appropriate FDA/IND documentations for proposed human subject studies. The FOA is expected to be published in Winter 2019 with an expected application due date in March 2019. The FOA will utilize the R21 activity code. Details of the planned FOA are provided below. |
| Version: | 1 |
Write CSS OR LESS and hit save. CTRL + SPACE for auto-complete.
